Medicine - Xagena

Medicine

News

Drugs

Xapedia

Farmaci

Farmacia

Medicina

Specialità

EMA: positive benefit-risk balance of topical formulations of Ketoprofen

Parkinson's disease: Stalevo linked to possible development of prostate carcinoma

Sartans linked to risk of cancer

High-dose Simvastatin associated with increased risk of muscle injury

Olmesartan linked to cardiovascular events

Angiotensin receptor blockers linked to tumor: FDA is conducting a safety review

Meridia is contraindicated in patients with history of cardiovascular disease or uncontrolled hypertension

HIV infection: Saquinavir in combination with Ritonavir linked to abnormal heart rhythm

Zyprexa: use in adolescents and safety informations

Increase in risk of diabetes and cardiovascular diseases in men treated with GnRH agonists

Acute myeloid leukaemia: Pfizer has voluntarily withdrawn Mylotarg

Acute coronary syndromes: Ticagrelor, a better option than Clopidogrel for patients undergoing invasive procedures

Diclofenac linked to high risk of cardiovascular deaths among healthy people

Low-dose Acetylsalicylic Acid may benefit older people with diabetes at high cardiovascular risk ( 2010 )

Mirena LNG-IUS appears to prevent the development of benign endometrial polyps in breast carcinoma patients taking Tamoxifen

Abatacept for rheumatoid arthritis: moderate-level evidence regarding efficacy and safety

Vitamin-D supplementation for cystic fibrosis: no evidence of benefit or harm

SAMe for osteoarthritis of the knee or hip: routine use should not be advised

Doxycycline should not be recommended for the treatment of osteoarthritis of the knee or hip

Acute postoperative pain in adults: single dose oral Ketoprofen and Dexketoprofen

Chronic neuropathic pain in adults: topical Capsaicin

Diabetic macular oedema: antiangiogenic therapy with Bevacizumab

Formoterol versus Salmeterol for chronic asthma: serious adverse events

Pediatric patients: use of antipsychotics associated with significant weight gain

Tibolone increases risk of recurrence in breast tumor survivors

Postmenopausal breast cancer: role of bisphosphonates

Head and neck tumor: Cetuximab increases survival for up to 5 years

Acetylsalicylic acid use after colorectal tumor diagnosis associated with improved survival

Renal cell carcinoma: interventional cryoablation is effective

Advanced non-small cell lung cancer: Vandetanib has shown clinical benefit when combined with Docetaxel

Hedgehog inhibitor yields positive response in people with advanced basal cell skin cancer and with medulloblastoma

Myocardial infarction: patients treated with more antithrombotics have increased risk of hospital admission for bleeding

Methylprednisolone added to Interferon beta-1a reduces relapse rate in patients with relapsing-remitting multiple sclerosis

Progressive multifocal leukoencephalopathy: JC virus is found to be reactivated in multiple sclerosis patients receiving Natalizumab

EGFR mutations in non-small-cell lung cancer: Gefitinib improves survival compared with standard chemotherapy

Advanced kidney cancer: Sunitinib shows promising results in patients with poor prognosis

Inoperable hepatocellular carcinoma: Lapatinib shows minimal effect

Sorafenib improves progression free survival in patients with breast cancer

Bevacizumab improves hearing in some patients with neurofibromatosis type 2

Bevacizumab is no different in effectiveness as Ranibizumab, the gold standard treatment for age-related macular degeneration

CT imaging may predict survival in patients with metastatic colorectal cancer treated with Bevacizumab

Head and neck cancer: Cetuximab continues to increase survival in patients for up to 5 years

Colorectal cancer with inoperable metastatic liver lesions: addition of Cetuximab to chemotherapy increases tumor shrinkage

Rituximab reduces inflammation in patients with lupus nephritis

Maintenance Rituximab is useful for advanced indolent lymphoma

Immune thrombocytopenic purpura: Eltrombopag boosts platelets

Rheumatoid arthritis: patients who fails to respond to initial treatment with Rituximab can still be successfully re-treated with a second course of drug

Graves' orbitopathy: Rituximab is effective after steroids fail

Aggressive inflammatory breast cancer: treatment with Lapatinib

Metastatic HER2+ breast cancer: triple drug combination is promising option

HEAAL Study: higher dose of Losartan significantly reduced deaths and hospitalizations due to heart failure

Antipsychotic drugs: use of Olanzapine by children and adolescents associated with high weight gain

Antipsychotics may contribute to inflammatory processes

Schizophrenia: Clozapine is associated with lower mortality, Quetiapine with the highest risk

Pazopanib in treating patients with aggressive thyroid cancer

Acute coronary syndromes: Ticagrelor is the first antiplatelet agent to demonstrate a reduction in cardiovascular death

Angioplasty: high-dose Clopidogrel combined with usual doses of Acetylsalicylic Acid may be an optimal treatment strategy

Myocardial infarction: patients treated with more antithrombotic drugs have increased risk of hospital admission for bleeding

Juvenile idiopathic arthritis: treatment with Etanercept

Risk of tuberculosis with anti-TNF agents

Advanced kidney cancer: Sunitinib shows promising results in patients with poor prognosis

Cetuximab increases survival in patients with head and neck cancer for up to 5 years

Chronic myeloid leukemia: Nilotinib and Dasatinib evoke faster response than Imatinib

Bevacizumab controls macular edema related to diabetes and to cataract surgery

Colorectal cancer: new treatments offer better survival

Bevacizumab dramatically improves response, survival in recurrrent glioblastoma

Breast cancer survival improves using Herceptin with chemotherapy

Anemia: stroke risk from Aranesp

Potential risk of male breast cancer with Finasteride

Removab for treatment of malignant ascites

Long-term data for Odanacatib: positive results in treating osteoporosis

Insulin glargine, possible cancer link

Raxibacumab for treatment of inhalation anthrax disease

Hypercholesterolemia: Pitavastatin is non-inferior to Atorvastatin and Simvastatin

Potential risk of meningiomas with high-dose Cyproterone acetate

Breast cancer: oligohydramnios associated with Herceptin

Risk of histoplasmosis and other invasive fungal infections associated with Enbrel

ODAC recommends against approving Tarceva for first-line maintenance use in advanced non-small cell lung cancer

Kalbitor for treating potentially life-threatening attacks of hereditary angioedema

Advanced breast cancer patients: Denosumab is superior to Zometa in reducing risk of developing multiple skeletal related events

Hepatic effects linked to Voltaren gel

Anticoagulants in the prevention of venous thromboembolism and recurrent miscarriage

Safety questions on Sibutramine, an appetite suppressant

Caution should be exercised when using non-steroidal anti-inflammatory drugs in patients with established, or a risk of, renal impairment

Influenza: safety information on Tamiflu and Relenza

Plavix: avoid use with Omeprazole

ACE inhibitors and angiotensin II receptor antagonists: recommendations on use during pregnancy and breastfeeding

Severe hypersensitivity reactions during infusion of Temsirolimus

Antiepileptics: adverse effects on bone

Altered kidney function in patients using Byetta

Movement disorders linked to Metoclopramide

Celtura, a cell culture-based influenza A/H1N1 pandemic vaccine

Diabetes: possible link between Lantus and cancer

Rheumatoid arthritis: Rituximab linked to progressive multifocal leukoencephalopathy

Chronic lymphocytic leukaemia: FDA has approved Arzerra

Advanced form of kidney cancer: Votrient approved

Heterozygous familial hypercholesterolemia: Crestor for use in pediatric patients

New indication for Gardasil: to prevent condyloma acuminata in men and boys

Ongoing safety review of Exjade

Kidney failure linked to Byetta, a drug for type 2 diabetes mellitus

Pagine successive 1 [2] 3

Link

Specialità

Patologie

Patologie

© XAGENA 2010 - P.IVA: 04454930969 - REA: 1748680 - Tutti i diritti riservati